Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.

Cancer cytopathology - 1 May 2026

Pighi Chiara, Settanni Giulio, Angelini Marta, Bortesi Laura, Viassolo Valeria, Ceccaroni Marcello, Bruni Francesco, Gori Stefania, Zannoni Gian Franco, Pesci Anna

Abstract excerpt

BACKGROUND: BRCA1/2 testing is currently recommended at diagnosis for high-grade serous ovarian carcinoma (HGSOC) because of its impact on patients' survival when treated with poly(adenosine diphosphate ribose) polymerase inhibitors. Standard clinical practice involves analyzing BRCA1/2 genes in formalin-fixed, paraffin-embedded (FFPE) histological specimens. However, because neoplastic ascites is a common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ascites
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Cystadenocarcinoma, Serous

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42046206
DOI: 10.1002/cncy.70102
PMCID: PMC13121880

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.PMID 42046206Read ↗

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysisSemantic proximity Read ↗

Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.Semantic proximity Read ↗

Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.Semantic proximity Read ↗

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.Semantic proximity Read ↗

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.Semantic proximity Read ↗

Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer.Semantic proximity Read ↗

Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens.Semantic proximity Read ↗

Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancerSemantic proximity Read ↗

Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.Semantic proximity Read ↗

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies.Semantic proximity Read ↗

Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.Semantic proximity Read ↗

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.